Overview

A Study of LY2127399 in Participants With Systemic Lupus Erythematosus

Status:
Completed
Trial end date:
2015-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this SLE study is to evaluate the efficacy, safety and tolerability of two different doses of LY2127399 administered in participants with active SLE.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Anti-Inflammatory Agents
Anti-Inflammatory Agents, Non-Steroidal
Antibodies, Monoclonal
Antimalarials
Immunosuppressive Agents